MarketPR
stockholders approved amendments to the company's 2020 Equity Plan at its annual meeting on September 30, 2026, authorizing an additional 650,000 shares of common stock for issuance.
The vote increased the total number of shares available under the plan to 765,061. The company filed a Form 8-K with the U.S. Securities and Exchange Commission on October 1, 2026, to report the meeting results.
The annual meeting was held at 12:00 p.m. As of the August 10, 2026 record date, CNS Pharmaceuticals had 1,461,449 shares of common stock issued and outstanding.
Of these, 668,188 shares, representing 45.72% of the total, were present in person or by proxy, establishing a quorum for the vote.
Keep reading